Why your annual flu shot might work differently each year
NCT ID NCT04576377
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study in Hong Kong enrolled 977 adults aged 18-45 to understand how getting the flu vaccine year after year changes the body's immune response. Participants received either the Flublok vaccine or a saline placebo. Researchers measured antibody levels and looked for reasons why some vaccinated people still catch the flu. The goal is to improve future flu vaccination strategies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Flublok (recombinant quadrivalent influenza vaccine)
- What this could lead to
- If successful, this study could help predict who benefits most from annual flu shots and why some vaccinated people still get the flu.
- What could go wrong
- This is an observational knowledge-harvesting study, not a test of a new treatment. Results may not apply to older adults or other populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
977 people
The number who actually took part.
- Started
-
Oct 2020
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18-45 years at enrolment. * Capable of providing informed consent. * Resident in Hong Kong in the coming 2 years. Exclusion Criteria: * Vaccinated against influenza in the past 24 months. * Included in one of the priority groups to receive influenza vaccination in Hong Kong (priority groups include pregnant women, long-stay residents of institutions for persons with disability, persons with chronic medical problems (chronic cardiovascular, lung, metabolic or kidney diseases, obesity (body mass index 30 or above) and chronic neurological condition), healthcare workers or persons working in poultry, pig farming or pig slaughtering industry). * With diagnosed medical conditions related to their immune system. * Currently taking medication for any condition that impairs immune system. * Individuals who report medical conditions not suitable to receive inactivated influenza vaccines, such as: Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine; or to a vaccine component; moderate or severe acute illness with or without fever after any previous influenza vaccination; or a history of Guillain-Barré syndrome (GBS) within 6 weeks of previous influenza vaccination. * Individuals, who report medical conditions not suitable to receive intramuscular injection, such as bleeding disorders; habitually taking anticoagulants (with the exception of antiplatelets such as aspirin). * Individuals who have any medical conditions not suitable to receive inactivated influenza vaccines as determined by a clinician.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Influenza, human are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Hong Kong
Hong Kong, 00000, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose to block the flu: baloxavir put to the test in households
- Can mRNA technology outsmart the flu in older adults?
- One shot, two protections? a new vaccine aims to tackle flu and COVID together
- Can a lab-made flu vaccine outperform the traditional egg-based shot?
- Bedside flu shot for heart patients: a simple strategy to save lives?
- New hope for tiniest flu patients: IV zanamivir tested in infants under 6 months